Cargando…

P075 Feasibility of 12 weeks melatonin supplementation in Mild Cognitive Impairment

INTRODUCTION: Melatonin has been hypothesised to slow cognitive decline in older adults due to its proposed multiple therapeutic benefits. METHODS: Participants with Mild Cognitive Impairment (MCI) were recruited from the community for a pilot 12-week randomised placebo-controlled trial of 25mg oral...

Descripción completa

Detalles Bibliográficos
Autores principales: Menczel Schrire, Z, Phillips, C, Duffy, S, Marshall, N, Mowszowski, L, LaMonica, H, Gordon, C, Naismith, S, Grunstein, R, Hoyos, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10109307/
http://dx.doi.org/10.1093/sleepadvances/zpac029.145
_version_ 1785027035360395264
author Menczel Schrire, Z
Phillips, C
Duffy, S
Marshall, N
Mowszowski, L
LaMonica, H
Gordon, C
Naismith, S
Grunstein, R
Hoyos, C
author_facet Menczel Schrire, Z
Phillips, C
Duffy, S
Marshall, N
Mowszowski, L
LaMonica, H
Gordon, C
Naismith, S
Grunstein, R
Hoyos, C
author_sort Menczel Schrire, Z
collection PubMed
description INTRODUCTION: Melatonin has been hypothesised to slow cognitive decline in older adults due to its proposed multiple therapeutic benefits. METHODS: Participants with Mild Cognitive Impairment (MCI) were recruited from the community for a pilot 12-week randomised placebo-controlled trial of 25mg oral melatonin to target brain oxidative stress and cognition. Primary outcomes were feasibility, acceptability, and tolerability. Secondary outcomes were brain oxidative stress (magnetic resonance spectroscopy) and cognition at 12 weeks. RESULTS: The study recruited 40 participants who were randomised to receive melatonin or placebo. Feasibility of recruitment, calculated by the percent of individuals who met inclusion and exclusion criteria on screening, was 42/389, 11%. The most common exclusion criteria met was age. Acceptability of intervention, defined as the number of participants who agreed to be randomised, was 40/42, 95%. At 12 weeks, adherence data collected by both medication diaries and pill counting was over the 80% threshold for all participants. Additionally, 38 participants completed MRI scans and 40 participants completed the cognitive assessment battery, providing preliminary data to support future trials. DISCUSSION: The results of this feasibility trial demonstrate challenge to find individuals in the general community that fit the criteria for MCI. However, once recruited, this population has shown the ability to follow the protocol and adhere to the trial medication. These results will inform a future definitive randomised controlled trial to specifically test the efficacy of melatonin on modifiable risk factors of dementia, as well as cognition and brain function.
format Online
Article
Text
id pubmed-10109307
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-101093072023-05-15 P075 Feasibility of 12 weeks melatonin supplementation in Mild Cognitive Impairment Menczel Schrire, Z Phillips, C Duffy, S Marshall, N Mowszowski, L LaMonica, H Gordon, C Naismith, S Grunstein, R Hoyos, C Sleep Adv Poster Presentations INTRODUCTION: Melatonin has been hypothesised to slow cognitive decline in older adults due to its proposed multiple therapeutic benefits. METHODS: Participants with Mild Cognitive Impairment (MCI) were recruited from the community for a pilot 12-week randomised placebo-controlled trial of 25mg oral melatonin to target brain oxidative stress and cognition. Primary outcomes were feasibility, acceptability, and tolerability. Secondary outcomes were brain oxidative stress (magnetic resonance spectroscopy) and cognition at 12 weeks. RESULTS: The study recruited 40 participants who were randomised to receive melatonin or placebo. Feasibility of recruitment, calculated by the percent of individuals who met inclusion and exclusion criteria on screening, was 42/389, 11%. The most common exclusion criteria met was age. Acceptability of intervention, defined as the number of participants who agreed to be randomised, was 40/42, 95%. At 12 weeks, adherence data collected by both medication diaries and pill counting was over the 80% threshold for all participants. Additionally, 38 participants completed MRI scans and 40 participants completed the cognitive assessment battery, providing preliminary data to support future trials. DISCUSSION: The results of this feasibility trial demonstrate challenge to find individuals in the general community that fit the criteria for MCI. However, once recruited, this population has shown the ability to follow the protocol and adhere to the trial medication. These results will inform a future definitive randomised controlled trial to specifically test the efficacy of melatonin on modifiable risk factors of dementia, as well as cognition and brain function. Oxford University Press 2022-11-09 /pmc/articles/PMC10109307/ http://dx.doi.org/10.1093/sleepadvances/zpac029.145 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Sleep Research Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Presentations
Menczel Schrire, Z
Phillips, C
Duffy, S
Marshall, N
Mowszowski, L
LaMonica, H
Gordon, C
Naismith, S
Grunstein, R
Hoyos, C
P075 Feasibility of 12 weeks melatonin supplementation in Mild Cognitive Impairment
title P075 Feasibility of 12 weeks melatonin supplementation in Mild Cognitive Impairment
title_full P075 Feasibility of 12 weeks melatonin supplementation in Mild Cognitive Impairment
title_fullStr P075 Feasibility of 12 weeks melatonin supplementation in Mild Cognitive Impairment
title_full_unstemmed P075 Feasibility of 12 weeks melatonin supplementation in Mild Cognitive Impairment
title_short P075 Feasibility of 12 weeks melatonin supplementation in Mild Cognitive Impairment
title_sort p075 feasibility of 12 weeks melatonin supplementation in mild cognitive impairment
topic Poster Presentations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10109307/
http://dx.doi.org/10.1093/sleepadvances/zpac029.145
work_keys_str_mv AT menczelschrirez p075feasibilityof12weeksmelatoninsupplementationinmildcognitiveimpairment
AT phillipsc p075feasibilityof12weeksmelatoninsupplementationinmildcognitiveimpairment
AT duffys p075feasibilityof12weeksmelatoninsupplementationinmildcognitiveimpairment
AT marshalln p075feasibilityof12weeksmelatoninsupplementationinmildcognitiveimpairment
AT mowszowskil p075feasibilityof12weeksmelatoninsupplementationinmildcognitiveimpairment
AT lamonicah p075feasibilityof12weeksmelatoninsupplementationinmildcognitiveimpairment
AT gordonc p075feasibilityof12weeksmelatoninsupplementationinmildcognitiveimpairment
AT naismiths p075feasibilityof12weeksmelatoninsupplementationinmildcognitiveimpairment
AT grunsteinr p075feasibilityof12weeksmelatoninsupplementationinmildcognitiveimpairment
AT hoyosc p075feasibilityof12weeksmelatoninsupplementationinmildcognitiveimpairment